- Home
- EFOR vs PSNL Comparison
EFOR vs PSNL Comparison
Compare EFOR & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EFOR | PSNL |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EFOR | PSNL |
|---|---|---|
| Price | $31.56 | $17.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 941.2K | ★ 3.5M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $3,980,400,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $67.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.90 | $4.65 |
| 52 Week High | $33.78 | $18.89 |
Technical Indicators
Market Signals| Indicator | EFOR | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 64.90 |
| Support Level | $30.50 | $7.36 |
| Resistance Level | $33.78 | N/A |
| Average True Range (ATR) | 1.69 | 0.77 |
| MACD | -0.35 | 0.34 |
| Stochastic Oscillator | 54.79 | 66.83 |
Price Performance
Historical ComparisonAbout EFOR Everforth Inc. Common Stock
Everforth Inc is a technology and digital engineering company that helps organizations adapt, innovate, and thrive in a world of constant change. It has six solution areas: AI & data, cloud and infrastructure, digital engineering, customer experience, cybersecurity, and enterprise platforms - accelerate time to value for commercial and federal clients.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.